Asna Latif, a PhD Candidate at University of Alberta, is the February 2025 Highlighted Trainee Author for JPET. Her research addresses the role of pharmacogenomics in cancer therapy, specifically the development of hearing loss due to cisplatin treatment: doi.org/10.1016/j.jpet….

A team from University of South Carolina and Southern Research identified compounds that allosterically modulate the dopamine transporter inhibiting TAT-mediated DAT inhibition. Such compounds provide hope that novel treatments for HAND are forthcoming: doi.org/10.1124/jpet.1….

A research team from Qingdao University Medical College and Fudan University demonstrated that a novel compound (QLS-278) inhibits NaV1.7 channels, thereby inhibiting multiple models of pain without sedative actions: doi.org/10.1124/jpet.1….

An research team from Poland and the US developed a novel ligand (PZKKN-94) that has both agonist and antagonist functions at serotonin receptors. Their data provides hope that additional therapeutics for Parkinson’s disease can be developed: doi.org/10.1016/j.jpet….

ASPET’s JPET (ASPET) and @PhRMAFoundation are partnering on a Challenge Award competition—a prize of $5,000—to the first author of up to five winning papers! Submit your papers on the #pharmacology of next gen therapeutics by July 1, 2025. 🔗Learn more: phrmafoundation.org/grants-fellows…

Ana Jiménez-Torres, Postdoctoral Research Fellow at the University of South Carolina College of Pharmacy, is a Highlighted Trainee Author for JPET. Her research identifies potential therapeutic agents to normalize dopamine dynamics in the brain to treat neurocognitive disease in HIV patients: doi.org/10.1124/jpet.1…

Mia Allen, a Neuroscience PhD Candidate at Wake Forest University School of Medicine, is the April 2025 Highlighted for JPET. The goal of her research is to identify and evaluate potential treatment approaches for cocaine-use disorder. Read more: doi.org/10.1016/j.jpet…. #cocaineusedisorder #neuroscience

Researchers have shown that metformin could exert beneficial effects on obesity-related kidney disease, in part by exerting effects on renal lipidomics. These findings should also have implications for developing targeted therapeutic strategies for ORKD: doi.org/10.1016/j.jpet….

Researchers show that a novel, potent, and selective LPA1 antagonist, referred to as ACT-1016-0707, demonstrated robust antifibrotic and anti-inflammatory activity in different lung fibrosis models. Read the article: doi.org/10.1016/j.jpet….

Tongzhen Xie, a postdoctoral associate at Boston University is the May 2025 Highlighted Trainee Author for JPET. Her research focuses on measuring neuronal activity through calcium signaling, a crucial process in pain transduction. Read here: doi.org/10.1016/j.jpet….

ASPET’s JPET and @PhRMAFoundation are partnering on a Challenge Award competition—a prize of $5,000—that will award trainees for outstanding papers addressing the #pharmacology of next generation therapeutics! 📆Submit by July 1, 2025. 🔗Learn more: phrmafoundation.org/grants-fellows…

This study demonstrates that combined hormone therapy with bazedoxifene plus conjugated estrogen significantly improves symptoms of menopausal depression. The findings highlight the potential of targeted hormone treatments for menopausal mental health. 🔗 ow.ly/pjAi50VWnbt

A group from Zydus Lifesciences Ltd. identified a new/novel GPR40 agonist (ZYDG2) that lacks the toxicity seen in fasiglifam and effectively increases GLP-1 and insulin levels, thereby treating type 2 diabetes. 🔗 Read the article here: doi.org/10.1016/j.jpet…

Researchers examined fexofenadine as a treatment for Pancreatic ductal adenocarcinoma. Oral administration could reach the tumor and reduce the total weight of the pancreas. If these results can be replicated, it may be used to treat patients with PDAC: doi.org/10.1016/j.jpet…

This study presents a novel design paradigm for tumor vaccines—combining MHC-II epitopes with nitrated CD4+ T-cell epitopes. The vaccines achieved superior antitumor efficacy and improved the immunosuppressive tumor microenvironment. 🔗 Read here: doi.org/10.1016/j.jpet….

Kerim Cakir, PhD student at Temple University School of Pharmacy, is the June 2025 HTA for JPET. Kerim’s research focuses on the current complication in the fentanyl supply in our community which is the introduction of alpha-2-agonists such as xylazine. 🔗Read here: doi.org/10.1016/j.jpet…

ASPET’s JPET (ASPET) and @PhRMAFoundation are partnering on a Challenge Award competition—a prize of $5,000—for outstanding papers addressing the #pharmacology of next generation therapeutics! 📆Submit by July 1, 2025. 🔗Learn more: phrmafoundation.org/grants-fellows…

📢Two weeks left — Early-career researchers, submit your research today! JPET and @PhRMAFoundation are partnering on a Challenge Award competition for outstanding papers addressing the #pharmacology of next gen therapeutics. 📆 Deadline: July 1, 2025 🔗 phrmafoundation.org/grants-fellows…

📢Early-career researchers, there's one week left to submit your research! JPET and @PhRMAFoundation are partnering on a Challenge Award competition for outstanding papers addressing the #pharmacology of next gen therapeutics. 📆 Deadline: July 1, 2025 🔗 phrmafoundation.org/grants-fellows…

An international multi-institutional group reported a phase 1 trial of a cyanide poisoning antidote in adults. This study paves the way for investigating stabilized isoamyl nitrite further as a potential emergency treatment for cyanide poisoning. Read: doi.org/10.1016/j.jpet…